Australian Brandon Starc has won the gold medal in the men's high jump at the Gold Coast Commonwealth Games.
Reported by Brisbane Times 38 minutes ago.
Starc claims Australia's first high jump Games gold since 1994
↧
↧
Australia: Class Actions In Australia—2017 Year In Review - Jones Day
Twenty-five years after the introduction of Australia's federal class action regime, class action law remains a significant element of the country's litigation landscape.
Reported by Mondaq 51 minutes ago.
↧
"Brokers" - cast: Christopher Egan, Hanna Griffiths, Gyton Grantley
*Release date :* TBA 2018
*Synopsis :* Set in 1994 Sydney, Australia and New York, the film is based on a true story, written by Wallace, about ... Reported by AceShowbiz 39 minutes ago.
*Synopsis :* Set in 1994 Sydney, Australia and New York, the film is based on a true story, written by Wallace, about ... Reported by AceShowbiz 39 minutes ago.
↧
Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
Major investment by Coalition for Epidemic Preparedness Innovations (CEPI) to advance vaccine development and manufacturing on two of CEPI’s highest priority infectious diseases
PLYMOUTH MEETING, Pa. and OSLO, Norway, April 11, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and CEPI – the Coalition for Epidemic Preparedness Innovations – today announced a partnership under which Inovio will develop vaccine candidates against Lassa fever and Middle East Respiratory Syndrome (MERS).CEPI will fund up to $56,000,000 to support Inovio’s pre-clinical and clinical advancement through Phase 2 of INO-4500, its Lassa fever vaccine, and INO-4700, its MERS vaccine. The shared goal of Inovio and CEPI is for the Lassa and MERS vaccines to be available as soon as possible for emergency use.
This is the second company agreement CEPI has signed since its launch in 2017. These partnerships represent an innovative approach to funding vaccine development, unlocking research and development potential so that vaccines are ready for efficacy studies during an outbreak. The agreement will enable funding for Inovio’s development efforts over a five-year period. The partnership agreement also includes options, not counted in the total above, to establish investigational stockpiles of both vaccines.
Lassa fever is a disease endemic to West Africa associated with annual outbreaks. An ongoing outbreak in Nigeria has, according to figures from the Nigerian Centre for Disease Control, resulted in over 400 confirmed cases and over 100 deaths from January 1, 2018 through April 8, 2018^1. MERS, first identified in 2012, causes a severe respiratory illness and has been associated with a number of outbreaks in Saudi Arabia and neighboring countries.
Individuals acquiring these diseases in the regions of origin occasionally travel to other locations, becoming ill in areas outside the endemic regions. In 2015 an individual with MERS returned to South Korea from the Middle East. This resulted in an outbreak that resulted in 186 confirmed cases and 38 deaths. The outbreak affected 24 hospitals, led to the temporary closure of more than 2,000 schools, and had a significant impact on the South Korean economy.
Richard Hatchett, CEO of CEPI, said, “Epidemics don’t respect borders; they destroy lives and devastate economies and we need to move swiftly to prepare for them. Partnering with Inovio is a considerable move forward for CEPI’s vaccine portfolio and developing a global insurance policy against these diseases.”
CEPI’s funding will support development up to the end of Phase 2, providing clinical safety and immunological data, and the establishment of investigational stockpiles that will be ready for clinical efficacy trial testing during outbreaks.
CEPI’s portfolio of investments will provide additional benefits to the wider vaccine community through the development of assays, reference standards and associated knowledge that may accelerate the development of other vaccines and medical counter measures against Lassa fever and MERS.
Dr. J. Joseph Kim, Inovio’s President & CEO, said, “The Inovio/CEPI partnership demonstrates the confidence of both organizations in Inovio’s DNA vaccine platform to rapidly produce countermeasures against emerging viral threats potentially protecting large populations from a pandemic. A key demonstration of such capabilities was that Inovio was the first organization to develop, manufacture and report positive human data from a Zika vaccine in less than seven months – when traditional vaccines take several years to reach this point. We look forward to addressing the global health challenges of emerging infectious diseases.”
Inovio will develop these DNA vaccines employing its ASPIRE™ (Antigen SPecific Immune REsponses) platform. This platform delivers optimized synthetic antigenic genes into cells, where they are translated into protein antigens that activate an individual's immune system to generate robust targeted T cell and antibody responses. Inovio’s immunotherapies function exclusively in vivo, and have generated an antigen-specific immune response against targeted diseases in all clinical trials to date.
The CEPI partnership builds upon Inovio’s clinical and preclinical advancements for MERS and Lassa fever vaccines. Results from a first-in-human Phase 1 study for its MERS vaccine found high levels of binding antibodies in 92% (57 of 62) of evaluated subjects. Significant antigen-specific cytotoxic T-lymphocyte (CTL) responses were also observed. Importantly, all but one evaluated vaccinated subject or 98% (61 of 62) generated an antibody and/or T cell response against the MERS vaccine. Inovio’s Lassa vaccine data also holds much promise^2. In a study funded by a $3.5 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), Inovio previously published that its DNA vaccine against Lassa fever provided 100% protection for non-human primates challenged with a lethal dose of the virus^3.
Inovio is advancing MERS and Lassa vaccines with the support of its collaborators: The Wistar Institute, Laval University, the NIH’s Rocky Mountain Laboratories, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), VGXI/GeneOne Life Science and the International Vaccine Institute.
*About MERS*
Middle East Respiratory Syndrome is caused by the MERS-Corona virus, part of the same family of viruses that causes the common cold and SARS (Severe Acute Respiratory Syndrome). It is transmitted from animals to humans and can be further transmitted by person to person contact. Symptoms include severe acute respiratory illness with fever, cough and shortness of breath as well as gastrointestinal symptoms, which can lead to death.
*About Lassa Fever*
Lassa fever is also known as Lassa hemorrhagic fever. The Lassa virus is transferred to humans from animals, most commonly by the Mastomys rodent. The virus can spread from person to person via bodily fluids and causes a range of symptoms including vomiting, swelling of the face, bleeding, and pain in the chest, back and abdomen.
*About CEPI*
CEPI is an innovative partnership between public, private, philanthropic and civil organizations founded in Davos in 2017.
To date, CEPI has received multi-year funding from Norway, Germany, Japan, the Bill & Melinda Gates Foundation and Wellcome. CEPI has also received single-year investments from the governments of Australia, Belgium, and Canada. It has reached $630 million of its target $1 billion funding target. The European Commission has announced a contribution in kind of €250 million that will support relevant projects through EC mechanisms.
Since its launch in January 2017, CEPI has announced two Calls for Proposals. The first was for candidate vaccines against MERS-COV, Nipah and Lassa viruses. The second was for the development of platforms that can be used for rapid vaccine development against unknown pathogens.
*About Inovio Pharmaceuticals, Inc.*
Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating CD8+ T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing clinical stage product pipeline, including candidates in Phase 3 and Phase 2. Partners and collaborators include MedImmune, Regeneron, Genentech, The Wistar Institute, University of Pennsylvania, the Parker Institute for Cancer Immunotherapy, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs, including the planned initiation and conduct of clinical trials and the availability and timing of data from those trials, and the sufficiency of our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our pipeline of SynCon® active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2017 and other regulatory filings we make from time to time. There can be no assurance that any product candidate in Inovio's pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and Inovio undertakes no obligation to update or revise these statements, except as may be required by law.
^1 http://ncdc.gov.ng/diseases/sitreps/?cat=5&name=An update of Lassa fever outbreak in Nigeria
^2 http://ir.inovio.com/news-and-media/news/press-release-details/2017/Inovio-Reports-New-Positive-Clinical-Data-on-Vaccine-Advances--in-the-Fight-Against-Emerging-Infectious-Diseases/default.aspx
^3 http://ir.inovio.com/news-and-media/news/press-release-details/2015/Inovio-Pharmaceuticals-DNA-Vaccine-Protects-100-Against-Deadly-MERS-Virus-in-Non-Human-Primates/default.aspx
*Contacts*
*For CEPI*
Rachel Grant
Phone: +44(0)7891249190
Email: Rachel.Grant@cepi.net
*For Inovio*
Investors:
Ben Matone
Phone: 484-362-0076
Email: ben.matone@inovio.com
Media:
Jeff Richardson
Phone: 267-440-4211
Email: jrichardson@inovio.com Reported by GlobeNewswire 50 minutes ago.
PLYMOUTH MEETING, Pa. and OSLO, Norway, April 11, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and CEPI – the Coalition for Epidemic Preparedness Innovations – today announced a partnership under which Inovio will develop vaccine candidates against Lassa fever and Middle East Respiratory Syndrome (MERS).CEPI will fund up to $56,000,000 to support Inovio’s pre-clinical and clinical advancement through Phase 2 of INO-4500, its Lassa fever vaccine, and INO-4700, its MERS vaccine. The shared goal of Inovio and CEPI is for the Lassa and MERS vaccines to be available as soon as possible for emergency use.
This is the second company agreement CEPI has signed since its launch in 2017. These partnerships represent an innovative approach to funding vaccine development, unlocking research and development potential so that vaccines are ready for efficacy studies during an outbreak. The agreement will enable funding for Inovio’s development efforts over a five-year period. The partnership agreement also includes options, not counted in the total above, to establish investigational stockpiles of both vaccines.
Lassa fever is a disease endemic to West Africa associated with annual outbreaks. An ongoing outbreak in Nigeria has, according to figures from the Nigerian Centre for Disease Control, resulted in over 400 confirmed cases and over 100 deaths from January 1, 2018 through April 8, 2018^1. MERS, first identified in 2012, causes a severe respiratory illness and has been associated with a number of outbreaks in Saudi Arabia and neighboring countries.
Individuals acquiring these diseases in the regions of origin occasionally travel to other locations, becoming ill in areas outside the endemic regions. In 2015 an individual with MERS returned to South Korea from the Middle East. This resulted in an outbreak that resulted in 186 confirmed cases and 38 deaths. The outbreak affected 24 hospitals, led to the temporary closure of more than 2,000 schools, and had a significant impact on the South Korean economy.
Richard Hatchett, CEO of CEPI, said, “Epidemics don’t respect borders; they destroy lives and devastate economies and we need to move swiftly to prepare for them. Partnering with Inovio is a considerable move forward for CEPI’s vaccine portfolio and developing a global insurance policy against these diseases.”
CEPI’s funding will support development up to the end of Phase 2, providing clinical safety and immunological data, and the establishment of investigational stockpiles that will be ready for clinical efficacy trial testing during outbreaks.
CEPI’s portfolio of investments will provide additional benefits to the wider vaccine community through the development of assays, reference standards and associated knowledge that may accelerate the development of other vaccines and medical counter measures against Lassa fever and MERS.
Dr. J. Joseph Kim, Inovio’s President & CEO, said, “The Inovio/CEPI partnership demonstrates the confidence of both organizations in Inovio’s DNA vaccine platform to rapidly produce countermeasures against emerging viral threats potentially protecting large populations from a pandemic. A key demonstration of such capabilities was that Inovio was the first organization to develop, manufacture and report positive human data from a Zika vaccine in less than seven months – when traditional vaccines take several years to reach this point. We look forward to addressing the global health challenges of emerging infectious diseases.”
Inovio will develop these DNA vaccines employing its ASPIRE™ (Antigen SPecific Immune REsponses) platform. This platform delivers optimized synthetic antigenic genes into cells, where they are translated into protein antigens that activate an individual's immune system to generate robust targeted T cell and antibody responses. Inovio’s immunotherapies function exclusively in vivo, and have generated an antigen-specific immune response against targeted diseases in all clinical trials to date.
The CEPI partnership builds upon Inovio’s clinical and preclinical advancements for MERS and Lassa fever vaccines. Results from a first-in-human Phase 1 study for its MERS vaccine found high levels of binding antibodies in 92% (57 of 62) of evaluated subjects. Significant antigen-specific cytotoxic T-lymphocyte (CTL) responses were also observed. Importantly, all but one evaluated vaccinated subject or 98% (61 of 62) generated an antibody and/or T cell response against the MERS vaccine. Inovio’s Lassa vaccine data also holds much promise^2. In a study funded by a $3.5 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), Inovio previously published that its DNA vaccine against Lassa fever provided 100% protection for non-human primates challenged with a lethal dose of the virus^3.
Inovio is advancing MERS and Lassa vaccines with the support of its collaborators: The Wistar Institute, Laval University, the NIH’s Rocky Mountain Laboratories, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), VGXI/GeneOne Life Science and the International Vaccine Institute.
*About MERS*
Middle East Respiratory Syndrome is caused by the MERS-Corona virus, part of the same family of viruses that causes the common cold and SARS (Severe Acute Respiratory Syndrome). It is transmitted from animals to humans and can be further transmitted by person to person contact. Symptoms include severe acute respiratory illness with fever, cough and shortness of breath as well as gastrointestinal symptoms, which can lead to death.
*About Lassa Fever*
Lassa fever is also known as Lassa hemorrhagic fever. The Lassa virus is transferred to humans from animals, most commonly by the Mastomys rodent. The virus can spread from person to person via bodily fluids and causes a range of symptoms including vomiting, swelling of the face, bleeding, and pain in the chest, back and abdomen.
*About CEPI*
CEPI is an innovative partnership between public, private, philanthropic and civil organizations founded in Davos in 2017.
To date, CEPI has received multi-year funding from Norway, Germany, Japan, the Bill & Melinda Gates Foundation and Wellcome. CEPI has also received single-year investments from the governments of Australia, Belgium, and Canada. It has reached $630 million of its target $1 billion funding target. The European Commission has announced a contribution in kind of €250 million that will support relevant projects through EC mechanisms.
Since its launch in January 2017, CEPI has announced two Calls for Proposals. The first was for candidate vaccines against MERS-COV, Nipah and Lassa viruses. The second was for the development of platforms that can be used for rapid vaccine development against unknown pathogens.
*About Inovio Pharmaceuticals, Inc.*
Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating CD8+ T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing clinical stage product pipeline, including candidates in Phase 3 and Phase 2. Partners and collaborators include MedImmune, Regeneron, Genentech, The Wistar Institute, University of Pennsylvania, the Parker Institute for Cancer Immunotherapy, DARPA, GeneOne Life Science, Plumbline Life Sciences, ApolloBio Corporation, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. For more information, visit www.inovio.com.
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs, including the planned initiation and conduct of clinical trials and the availability and timing of data from those trials, and the sufficiency of our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our pipeline of SynCon® active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2017 and other regulatory filings we make from time to time. There can be no assurance that any product candidate in Inovio's pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and Inovio undertakes no obligation to update or revise these statements, except as may be required by law.
^1 http://ncdc.gov.ng/diseases/sitreps/?cat=5&name=An update of Lassa fever outbreak in Nigeria
^2 http://ir.inovio.com/news-and-media/news/press-release-details/2017/Inovio-Reports-New-Positive-Clinical-Data-on-Vaccine-Advances--in-the-Fight-Against-Emerging-Infectious-Diseases/default.aspx
^3 http://ir.inovio.com/news-and-media/news/press-release-details/2015/Inovio-Pharmaceuticals-DNA-Vaccine-Protects-100-Against-Deadly-MERS-Virus-in-Non-Human-Primates/default.aspx
*Contacts*
*For CEPI*
Rachel Grant
Phone: +44(0)7891249190
Email: Rachel.Grant@cepi.net
*For Inovio*
Investors:
Ben Matone
Phone: 484-362-0076
Email: ben.matone@inovio.com
Media:
Jeff Richardson
Phone: 267-440-4211
Email: jrichardson@inovio.com Reported by GlobeNewswire 50 minutes ago.
↧
Synup launches “CoinFriendly”, the World’s Largest Repository of Bitcoin-friendly Businesses
NEW YORK , April 11, 2018 (GLOBE NEWSWIRE) -- Synup, a provider of SaaS-based location intelligence, today announced the launch of a new website,* CoinFriendly.io. *With* 10,717 bitcoin-accepting businesses *listed on CoinFriendly, the website is the single largest repository of local businesses that accept cryptocurrency for transactional purposes. The new website will allow bitcoin users across the globe to identify these stores and services in 20 countries in North America, Europe, Asia, Australia and South America.With the increase in bitcoin adoption rates, the number of businesses that are now open to accepting any form of cryptocurrency has also been soaring. Bitcoins are now worth more than USD 6000, making it a highly valuable asset for cryptocurrency investors. While the debate on regulating digital currency surges on, the adoption rate has been growing tremendously, leading to a market capitalisation of over $250 billion. While early adopters chose to use bitcoin as an investment opportunity, new users are utilising their bitcoin as a cashless payment option.
Currently, North America leads in the number of bitcoin users, closely followed by Europe. One can also search for vendors through the website’s categorical search, which has listings of all kinds of businesses ranging from home services to restaurants and hotels. This is a valuable tool for locals as well as travellers.
Synup, the parent company owning CoinFriendly, has been supporting local businesses in the USA and Canada with improving their online presence since 2014. With CoinFriendly, Synup hopes to tap into the previously untapped cryptocurrency market, helping small and medium businesses improve their visibility amongst bitcoin users.
To know more about CoinFriendly, visit: http://coinfriendly.io/
*Supporting Quote*
*Ashwin Ramesh, Founder & CEO, Synup*
“We are proud to be launching the world’s most comprehensive directory of bitcoin friendly businesses. It was one of our most ambitious projects and we are very happy to see the final product. Coin Friendly is an effort to make cryptocurrency the de facto standard across the globe. Crypto is a reality and while some may argue about regulations and protocols, the current businesses that are accepting bitcoin need to be visible to the public.”
*About Synup*
Synup is a New York & Bangalore based startup with operations in US & Canada. Founded by serial entrepreneur, Ashwin Ramesh, Synup’s SaaS solution enables small businesses, marketers and brands to manage their location intelligence to ensure that consumers find the right information about them on web, mobile and voice search. Further details at: www.synup.com
CONTACT: Contact:
Synup
hello@synup.com Reported by GlobeNewswire 50 minutes ago.
Currently, North America leads in the number of bitcoin users, closely followed by Europe. One can also search for vendors through the website’s categorical search, which has listings of all kinds of businesses ranging from home services to restaurants and hotels. This is a valuable tool for locals as well as travellers.
Synup, the parent company owning CoinFriendly, has been supporting local businesses in the USA and Canada with improving their online presence since 2014. With CoinFriendly, Synup hopes to tap into the previously untapped cryptocurrency market, helping small and medium businesses improve their visibility amongst bitcoin users.
To know more about CoinFriendly, visit: http://coinfriendly.io/
*Supporting Quote*
*Ashwin Ramesh, Founder & CEO, Synup*
“We are proud to be launching the world’s most comprehensive directory of bitcoin friendly businesses. It was one of our most ambitious projects and we are very happy to see the final product. Coin Friendly is an effort to make cryptocurrency the de facto standard across the globe. Crypto is a reality and while some may argue about regulations and protocols, the current businesses that are accepting bitcoin need to be visible to the public.”
*About Synup*
Synup is a New York & Bangalore based startup with operations in US & Canada. Founded by serial entrepreneur, Ashwin Ramesh, Synup’s SaaS solution enables small businesses, marketers and brands to manage their location intelligence to ensure that consumers find the right information about them on web, mobile and voice search. Further details at: www.synup.com
CONTACT: Contact:
Synup
hello@synup.com Reported by GlobeNewswire 50 minutes ago.
↧
↧
Sport24.co.za | Who to watch: Team SA on Day 8
Day 8 at the Commonwealth Games on Australia's Gold Coast sees South Africa's Caster Semenya kickstart her 800m campaign.
Reported by News24 40 minutes ago.
↧
Capgemini SE : Successful outcome of the tender offer on Capgemini's 2020 bonds
*Not for distribution, directly or indirectly in *
*the United States of America, Canada, Australia and Japan*
*Investor Relations:*
Vincent Biraud
Tel.: +33 1 47 54 50 87
Email: vincent.biraud@capgemini.com
*Successful outcome of the tender offer on Capgemini's 2020 bonds*
* *
*Paris, April 11, 2018-* Capgemini reports on the successful results of the cash tender offer launched on April 3, 2018, by BNP Paribas on Capgemini's €1.25 billion bond maturing in July 2020 (the 2020 bond, ISIN FR0012821932) which expired on April 10, 2018: on the back of the significant participation to the tender, BNP Paribas announced today it has increased the aggregate principal amount of 2020 bonds that it intends to purchase to €574 million from the €500 million initially announced, for a total cash consideration of €597 million, excluding accrued interest.
This comes after the successful pricing by Capgemini on April 3, 2018, of €600 million 6.5-year 1.00% notes (the 2024 bond, ISIN FR0013327962) and €500 million 10-year 1.75% notes (the 2028 bond, ISIN FR0013327988).
As previously communicated, Capgemini intends to exchange all of the 2020 bonds acquired by BNP Paribas through the tender offer with 2024 bonds. Following the cancellation of the 2020 bonds brought to the exchange, the outstanding principal amount of 2020 bonds will be reduced to €676 million.
The proceeds from the 2028 bond and the balance remaining from the 2024 bond will be used for general corporate purposes, including the redemption of its €500 million bond maturing on July 2, 2018 (ISIN FR0012821924).
Through these transactions, which will have no significant impact on the total amount of the Group's debt, Capgemini takes advantage of current attractive market conditions to proactively manage its debt maturity profile.
The French financial market authority (AMF, Autorité des Marchés Financiers) granted on April 10, 2018, the visa number 18-126 on the prospectus relating to the issue by Capgemini of its 2024 and 2028 bonds. The issuance of these bonds and the exchange with BNP Paribas relating to the repurchased 2020 bonds are expected to settle on April 18, 2018.
** **
**DISCLAIMER**
This press release and the information contained herein do not constitute an offer to sell, purchase or subscribe, nor a solicitation of an order to purchase or subscribe the notes in any country, in particular in the United States nor is it a solicitation for acceptance of any tender offer mentioned in this press release. The distribution of this press release may be restricted in some countries and persons in possession of this press release should inform themselves about and comply with any applicable restrictions.
This press release is not an offer for sale of the notes in the United States or in any other jurisdiction. The notes may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Capgemini SE does not intend to register any portion of the offering mentioned in this press release in the United States or to conduct a public offering of the notes in the United States. The tender offer mentioned in this press release is made only by the offeror mentioned herein. The tender offer is not being made to (nor will tender of notes be accepted from or on behalf of) holders of notes in any jurisdiction (including the United States, Canada, Japan or Australia) in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.
This press release may contain information which could be deemed as forward-looking with respect to Capgemini SE's financial condition, results of operations, business, strategy or plans. Although Capgemini SE believes that such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance. Actual results may differ materially from the forward looking statements as a result of a number of risks and uncertainties, many of which are outside of our control, including but not limited to the risks regarding antitrust and regulatory approval as well as the risks described in the documents Capgemini SE has filed with the Autorité des Marchés Financiers (French financial markets authority) and which are also available in English and French on our website (www.capgemini.com). Investors and security holders may obtain a free copy of the documents filed by Capgemini SE with the Autorité des Marchés Financiers at www.amf-france.org, or directly from Capgemini SE. The present forward-looking statements are made as of the date of this press release and Capgemini SE reserves the right to provide, update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
*
*About Capgemini**
A global leader in consulting, technology services and digital transformation, Capgemini is at the forefront of innovation to address the entire breadth of clients' opportunities in the evolving world of cloud, digital and platforms. Building on its strong 50-year heritage and deep industry-specific expertise, Capgemini enables organizations to realize their business ambitions through an array of services from strategy to operations. Capgemini is driven by the conviction that the business value of technology comes from and through people. It is a multicultural company of 200,000 team members in over 40 countries. The Group reported 2017 global revenues of EUR 12.8 billion.
Visit us at www.capgemini.com. People matter, results count.
*Attachment*
· Successful outcome of the tender offer on Capgemini's 2020 bonds.pdf Reported by GlobeNewswire 50 minutes ago.
*the United States of America, Canada, Australia and Japan*
*Investor Relations:*
Vincent Biraud
Tel.: +33 1 47 54 50 87
Email: vincent.biraud@capgemini.com
*Successful outcome of the tender offer on Capgemini's 2020 bonds*
* *
*Paris, April 11, 2018-* Capgemini reports on the successful results of the cash tender offer launched on April 3, 2018, by BNP Paribas on Capgemini's €1.25 billion bond maturing in July 2020 (the 2020 bond, ISIN FR0012821932) which expired on April 10, 2018: on the back of the significant participation to the tender, BNP Paribas announced today it has increased the aggregate principal amount of 2020 bonds that it intends to purchase to €574 million from the €500 million initially announced, for a total cash consideration of €597 million, excluding accrued interest.
This comes after the successful pricing by Capgemini on April 3, 2018, of €600 million 6.5-year 1.00% notes (the 2024 bond, ISIN FR0013327962) and €500 million 10-year 1.75% notes (the 2028 bond, ISIN FR0013327988).
As previously communicated, Capgemini intends to exchange all of the 2020 bonds acquired by BNP Paribas through the tender offer with 2024 bonds. Following the cancellation of the 2020 bonds brought to the exchange, the outstanding principal amount of 2020 bonds will be reduced to €676 million.
The proceeds from the 2028 bond and the balance remaining from the 2024 bond will be used for general corporate purposes, including the redemption of its €500 million bond maturing on July 2, 2018 (ISIN FR0012821924).
Through these transactions, which will have no significant impact on the total amount of the Group's debt, Capgemini takes advantage of current attractive market conditions to proactively manage its debt maturity profile.
The French financial market authority (AMF, Autorité des Marchés Financiers) granted on April 10, 2018, the visa number 18-126 on the prospectus relating to the issue by Capgemini of its 2024 and 2028 bonds. The issuance of these bonds and the exchange with BNP Paribas relating to the repurchased 2020 bonds are expected to settle on April 18, 2018.
** **
**DISCLAIMER**
This press release and the information contained herein do not constitute an offer to sell, purchase or subscribe, nor a solicitation of an order to purchase or subscribe the notes in any country, in particular in the United States nor is it a solicitation for acceptance of any tender offer mentioned in this press release. The distribution of this press release may be restricted in some countries and persons in possession of this press release should inform themselves about and comply with any applicable restrictions.
This press release is not an offer for sale of the notes in the United States or in any other jurisdiction. The notes may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Capgemini SE does not intend to register any portion of the offering mentioned in this press release in the United States or to conduct a public offering of the notes in the United States. The tender offer mentioned in this press release is made only by the offeror mentioned herein. The tender offer is not being made to (nor will tender of notes be accepted from or on behalf of) holders of notes in any jurisdiction (including the United States, Canada, Japan or Australia) in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.
This press release may contain information which could be deemed as forward-looking with respect to Capgemini SE's financial condition, results of operations, business, strategy or plans. Although Capgemini SE believes that such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance. Actual results may differ materially from the forward looking statements as a result of a number of risks and uncertainties, many of which are outside of our control, including but not limited to the risks regarding antitrust and regulatory approval as well as the risks described in the documents Capgemini SE has filed with the Autorité des Marchés Financiers (French financial markets authority) and which are also available in English and French on our website (www.capgemini.com). Investors and security holders may obtain a free copy of the documents filed by Capgemini SE with the Autorité des Marchés Financiers at www.amf-france.org, or directly from Capgemini SE. The present forward-looking statements are made as of the date of this press release and Capgemini SE reserves the right to provide, update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
*
*About Capgemini**
A global leader in consulting, technology services and digital transformation, Capgemini is at the forefront of innovation to address the entire breadth of clients' opportunities in the evolving world of cloud, digital and platforms. Building on its strong 50-year heritage and deep industry-specific expertise, Capgemini enables organizations to realize their business ambitions through an array of services from strategy to operations. Capgemini is driven by the conviction that the business value of technology comes from and through people. It is a multicultural company of 200,000 team members in over 40 countries. The Group reported 2017 global revenues of EUR 12.8 billion.
Visit us at www.capgemini.com. People matter, results count.
*Attachment*
· Successful outcome of the tender offer on Capgemini's 2020 bonds.pdf Reported by GlobeNewswire 50 minutes ago.
↧
Interim HealthCare Inc. Named a Top Franchise Under $150K by Entrepreneur Magazine
Interim ranked No. 13 in the Top Franchises Under $150K category
SUNRISE, Fla. (PRWEB) April 11, 2018
Interim HealthCare Inc. is ranked No. 13 in the Top Franchises Under $150K category by Entrepreneur Magazine’s Spring Startups issue. This ranking is based off similar criteria to the Entrepreneur’s 2018 Franchise 500 but is stratified by three key investment levels: under $50k, $100k and $150k. Recognized as an invaluable resource for potential franchisees, Entrepreneur evaluates recipients based on outstanding performance in areas including unit growth, financial strength and stability, and brand power.
“The demand for dependable, high-quality home care services will continue to rise as growing numbers of seniors nationwide choose to age in place,” said Larry Kraska, Interim HealthCare Inc. CEO and President. “Meeting the needs of this aging population will continue to be in high demand. In fact, according to a recent article, healthcare is listed as the industry with the most promising future. An Interim HealthCare franchise is an affordable investment opportunity with great potential for expansion, and we couldn’t be prouder of this recognition.”
Interim HealthCare Inc. offers extensive training and innovative marketing programs for all franchisees through one of the most experienced franchise support teams in the industry. Its legendary brand has been built on over 50 years of home care, hospice and staffing expertise. Interim’s deep understanding of today’s regulatory environment and the complexities of building franchise operations, such as marketing, sales, finance, training and human resources, continues to drive business success for its franchise owners.
For more details about the company’s franchisee opportunities, visit http://www.interimfranchising.com.
Rankings will be published in the Spring issue of Entrepreneur’s Startups.
About Interim HealthCare Inc.
Interim HealthCare Inc., founded in 1966, is a leading national franchisor of home care, hospice and healthcare staffing. It is part of Caring Brands International which also includes UK-based Bluebird Care and Australia-based Just Better Care, both well-known franchise brands in their countries. With more than 530 franchise locations in seven countries Caring Brands International is a global health care leader.
Interim HealthCare in the United States is unique in combining the commitment of local ownership with the support of a national organization that develops innovative programs and quality standards that improve the delivery of service. Franchisees employ nurses, therapists, aides, companions and other healthcare professionals who provide 25 million hours of home care service to 190,000 people each year, meeting a variety of home health, senior care, hospice, palliative care, pediatric care and healthcare staffing needs. For more information or to locate an Interim HealthCare office, visit http://www.interimhealthcare.com. Reported by PRWeb 47 minutes ago.
SUNRISE, Fla. (PRWEB) April 11, 2018
Interim HealthCare Inc. is ranked No. 13 in the Top Franchises Under $150K category by Entrepreneur Magazine’s Spring Startups issue. This ranking is based off similar criteria to the Entrepreneur’s 2018 Franchise 500 but is stratified by three key investment levels: under $50k, $100k and $150k. Recognized as an invaluable resource for potential franchisees, Entrepreneur evaluates recipients based on outstanding performance in areas including unit growth, financial strength and stability, and brand power.
“The demand for dependable, high-quality home care services will continue to rise as growing numbers of seniors nationwide choose to age in place,” said Larry Kraska, Interim HealthCare Inc. CEO and President. “Meeting the needs of this aging population will continue to be in high demand. In fact, according to a recent article, healthcare is listed as the industry with the most promising future. An Interim HealthCare franchise is an affordable investment opportunity with great potential for expansion, and we couldn’t be prouder of this recognition.”
Interim HealthCare Inc. offers extensive training and innovative marketing programs for all franchisees through one of the most experienced franchise support teams in the industry. Its legendary brand has been built on over 50 years of home care, hospice and staffing expertise. Interim’s deep understanding of today’s regulatory environment and the complexities of building franchise operations, such as marketing, sales, finance, training and human resources, continues to drive business success for its franchise owners.
For more details about the company’s franchisee opportunities, visit http://www.interimfranchising.com.
Rankings will be published in the Spring issue of Entrepreneur’s Startups.
About Interim HealthCare Inc.
Interim HealthCare Inc., founded in 1966, is a leading national franchisor of home care, hospice and healthcare staffing. It is part of Caring Brands International which also includes UK-based Bluebird Care and Australia-based Just Better Care, both well-known franchise brands in their countries. With more than 530 franchise locations in seven countries Caring Brands International is a global health care leader.
Interim HealthCare in the United States is unique in combining the commitment of local ownership with the support of a national organization that develops innovative programs and quality standards that improve the delivery of service. Franchisees employ nurses, therapists, aides, companions and other healthcare professionals who provide 25 million hours of home care service to 190,000 people each year, meeting a variety of home health, senior care, hospice, palliative care, pediatric care and healthcare staffing needs. For more information or to locate an Interim HealthCare office, visit http://www.interimhealthcare.com. Reported by PRWeb 47 minutes ago.
↧
Australian birds hit by 'mysterious' illness
Birds in Western Australia's Perth have been hit by a mystery illness affecting motor skills that continues to allude scientists, a media report said.
Reported by Zee News 18 minutes ago.
↧
↧
The Singing Machine Company looks to expand internationally
The Singing Machine Company (OTCMKTS:SMDM) told Proactive Investors on Tuesday the at-home karaoke company has plans to expand internationally. The Florida-based company has products in several major US retailers, like Walmart and Target. Business in the UK has been growing 50% year-over-year. Recently, the company signed a distribution contract with Australia and is shipping its machines to China and Japan as well. This year, the karaoke company saw 20% growth and US$60mln in sales. In the wake of its second-largest client Toys R Us filing for Chapter 7, The Singing Machine Company had US$2mln in write-offs and foresees an additional US$1mln. CEO Gary Atkinson remains hopeful about the future of the industry. “The toy industry is still a very healthy industry. There’s really nothing wrong with the toy sector,” said Atkinson. “We see ourselves well-positioned to grow with all of the other retailers.” The company is introducing a new product for the summer called The Singing Machine Studio, which will combine karaoke and Auto-Tune software. It will be available for $199. Atkinson hopes the product will welcome a new demographic, making karaoke accessible to those who would other feel uncomfortable singing. Shares of The Singing Machine Company were down 1.60% on Wednesday morning.
Reported by Proactive Investors 23 seconds ago.
↧
Aussies spear gold and step out of the shadows
It was a big night on the track for Australia winning two gold medals, setting new records and winning two silver medals.
Reported by The Age 4 minutes ago.
↧
McMaster dedicates 1st medal to dead coach, and BVI people
GOLD COAST, Australia (AP) — Kyron McMaster had the message inked onto his arm, not that he needed any reminding of the coach to whom he was dedicating the British Virgin Islands first major international medal.McMaster won the...
Reported by New Zealand Herald 35 minutes ago.
↧
Beazley adds to its Technology, Media and Business Services team in Atlanta and New York
New York, April 12, 2018 (GLOBE NEWSWIRE) -- Specialist insurer Beazley has added two new underwriters to its Technology, Media and Business Services (TMB) team in the United States.
Justin Patrick has joined the team in Atlanta as regional manager, where he will be responsible for leading underwriting efforts and broker relations for TMB throughout the southeastern United States. Mr Patrick has extensive experience of both broking and underwriting. Before joining Beazley he was an underwriting director at CNA Financial Corporation where he managed a portfolio of management and professional liability lines for financial institutions.
Kristin Camme has joined the team in New York as an underwriter where she will focus on US middle market risks. Ms Camme is a member of the New York State Bar and has five years’ experience of privacy and professional liability underwriting and claims management. She joins Beazley from Chubb Group.
Bob Wice, TMB US focus group leader, said: “I’m delighted to welcome Justin and Kristin to our team of highly-experienced underwriters, adding to our local capabilities in Atlanta and New York. They join at a time when demand for our TMB products is growing strongly, especially for privacy and breach response coverage.”
-ends-
Note to editors:
Beazley plc (BEZ.L) is the parent company of specialist insurance businesses with operations in Europe, the US, Canada, Latin America, Asia and Australia. Beazley manages six Lloyd’s syndicates and in 2017 underwrote gross premiums worldwide of $2,344 million. All Lloyd’s syndicates are rated A by A.M. Best.
Beazley’s underwriters in the United States focus on writing a range of specialist insurance products. In the admitted market, coverage is provided by Beazley Insurance Company, Inc., an A.M. Best A rated carrier licensed in all 50 states. In the surplus lines market, coverage is provided by the Beazley syndicates at Lloyd’s.
Beazley is a market leader in many of its chosen lines, which include professional indemnity, property, marine, reinsurance, accident and life, and political risks and contingency business.
For more information please go to: www.beazley.com
BZPR_120418
CONTACT: Eleanor Lewis
Beazley Group
+44 (0)20 7667 0538
eleanor.lewis@beazley.com Reported by GlobeNewswire 41 minutes ago.
Justin Patrick has joined the team in Atlanta as regional manager, where he will be responsible for leading underwriting efforts and broker relations for TMB throughout the southeastern United States. Mr Patrick has extensive experience of both broking and underwriting. Before joining Beazley he was an underwriting director at CNA Financial Corporation where he managed a portfolio of management and professional liability lines for financial institutions.
Kristin Camme has joined the team in New York as an underwriter where she will focus on US middle market risks. Ms Camme is a member of the New York State Bar and has five years’ experience of privacy and professional liability underwriting and claims management. She joins Beazley from Chubb Group.
Bob Wice, TMB US focus group leader, said: “I’m delighted to welcome Justin and Kristin to our team of highly-experienced underwriters, adding to our local capabilities in Atlanta and New York. They join at a time when demand for our TMB products is growing strongly, especially for privacy and breach response coverage.”
-ends-
Note to editors:
Beazley plc (BEZ.L) is the parent company of specialist insurance businesses with operations in Europe, the US, Canada, Latin America, Asia and Australia. Beazley manages six Lloyd’s syndicates and in 2017 underwrote gross premiums worldwide of $2,344 million. All Lloyd’s syndicates are rated A by A.M. Best.
Beazley’s underwriters in the United States focus on writing a range of specialist insurance products. In the admitted market, coverage is provided by Beazley Insurance Company, Inc., an A.M. Best A rated carrier licensed in all 50 states. In the surplus lines market, coverage is provided by the Beazley syndicates at Lloyd’s.
Beazley is a market leader in many of its chosen lines, which include professional indemnity, property, marine, reinsurance, accident and life, and political risks and contingency business.
For more information please go to: www.beazley.com
BZPR_120418
CONTACT: Eleanor Lewis
Beazley Group
+44 (0)20 7667 0538
eleanor.lewis@beazley.com Reported by GlobeNewswire 41 minutes ago.
↧
↧
Newcrest Mining Limited Announces Equity Investment in Almadex Minerals Limited
MELBOURNE, Australia, April 12, 2018 (GLOBE NEWSWIRE) -- On February 26, 2018, Newcrest International Pty Ltd. (“NIPL”), a wholly-owned subsidiary of Newcrest Mining Limited (“Newcrest”), entered into a subscription agreement with Almadex Minerals Limited (the “Company”) to purchase 14,025,312 common shares in the capital of the Company, representing 19.9% of the issued and outstanding common shares (the “Common Shares”) at a price of C$1.36 per Common Share for an aggregate subscription price of $19,074,425 (the “Subscription Price”) by way of private placement (the “Private Placement”).Closing of the Private Placement is subject to certain customary conditions and the completion of a reorganization transaction (the “Spin-out Transaction”) in which certain assets of the Company will be transferred to a newly formed corporation, the shares of which will be distributed to the Company’s shareholders. Under the terms of the Subscription Agreement, the number of Common Shares to be acquired by Newcrest and the price per Common Share may be adjusted in certain instances so that Newcrest acquires 19.9% of the issued and outstanding Common Shares following closing of the Spin-out Transaction and the Private Placement for the Subscription Price.
Following the satisfaction of certain conditions, on April 11, 2018, NIPL placed the Subscription Price into escrow. As of April 11, 2018, it is expected that the issued and outstanding common shares of the Company, after giving effect to the Spin-out Transaction and the Private Placement, will be 72,070,998 and NIPL will acquire 14,342,129 common shares pursuant to the Private Placement. It is expected that the closing of the Private Placement will be on or about May 28, 2018.
Newcrest does not currently own or control any securities of the Company. Following the completion of the Spin-out Transaction and the Private Placement, Newcrest will have ownership or control over 14,342,129 Common Shares representing approximately 19.9% of the issued and outstanding Common Shares.
The Common Shares will be acquired by Newcrest for investment purposes, and in the future it may, from time to time, increase or decrease its investment in the Company through market transactions, private agreements, treasury issuances or otherwise at any time subject to applicable restrictions and depending on market conditions and any other relevant factors.
This news release is being issued under the early warning reporting provisions of applicable securities laws. An early warning report with additional information in respect of the foregoing matters will be filed and made available under the SEDAR profile of the Company at www.sedar.com. To obtain a copy of the early warning report, you may also contact Christopher Maitland on + 61 3 9522 5717. Newcrest’s address is Level 8, 600 St. Kilda’s Road, Melbourne, Victoria, Australia, 3004.
*Forward-Looking Information*
Certain statements in the press release are forward-looking statements and are prospective in nature, including statements with respect to Newcrest’s future intentions regarding the securities of the Company. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Such forward-looking statements should therefore be construed in light of such factors, and Newcrest is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Reported by GlobeNewswire 41 minutes ago.
Following the satisfaction of certain conditions, on April 11, 2018, NIPL placed the Subscription Price into escrow. As of April 11, 2018, it is expected that the issued and outstanding common shares of the Company, after giving effect to the Spin-out Transaction and the Private Placement, will be 72,070,998 and NIPL will acquire 14,342,129 common shares pursuant to the Private Placement. It is expected that the closing of the Private Placement will be on or about May 28, 2018.
Newcrest does not currently own or control any securities of the Company. Following the completion of the Spin-out Transaction and the Private Placement, Newcrest will have ownership or control over 14,342,129 Common Shares representing approximately 19.9% of the issued and outstanding Common Shares.
The Common Shares will be acquired by Newcrest for investment purposes, and in the future it may, from time to time, increase or decrease its investment in the Company through market transactions, private agreements, treasury issuances or otherwise at any time subject to applicable restrictions and depending on market conditions and any other relevant factors.
This news release is being issued under the early warning reporting provisions of applicable securities laws. An early warning report with additional information in respect of the foregoing matters will be filed and made available under the SEDAR profile of the Company at www.sedar.com. To obtain a copy of the early warning report, you may also contact Christopher Maitland on + 61 3 9522 5717. Newcrest’s address is Level 8, 600 St. Kilda’s Road, Melbourne, Victoria, Australia, 3004.
*Forward-Looking Information*
Certain statements in the press release are forward-looking statements and are prospective in nature, including statements with respect to Newcrest’s future intentions regarding the securities of the Company. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Such forward-looking statements should therefore be construed in light of such factors, and Newcrest is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Reported by GlobeNewswire 41 minutes ago.
↧
CHF Solutions, Inc. Expands Operations into Hong Kong; Receives First Commercial Orders for Both Hong Kong and Singapore
EDEN PRAIRIE, Minn., April 12, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) announced today its commercial expansion into the Hong Kong market through its Asia distributor, Transmedic. Further, Transmedic has confirmed its first commercial orders for both Singapore and Hong Kong."Our expansion into the Asian markets is a key factor in our commercialization strategy, and our distribution partner, Transmedic, has flawlessly initiated on executing that strategy,” commented John Erb, chairman and chief executive officer of CHF Solutions. “We believe the heart failure market for patients suffering from fluid overload remains largely untapped in Asia and that the Aquadex FlexFlow system provides a clinically proven alternative therapy option over pharmacotherapy.”
These commercial orders were for both Aquadex FlexFlow consoles and the corresponding disposable products.
*About CHF Solutions*
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
*CONTACTS:*
*INVESTORS:
*Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com
*MEDIA
*Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com Reported by GlobeNewswire 41 minutes ago.
These commercial orders were for both Aquadex FlexFlow consoles and the corresponding disposable products.
*About CHF Solutions*
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
*CONTACTS:*
*INVESTORS:
*Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com
*MEDIA
*Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com Reported by GlobeNewswire 41 minutes ago.
↧
Silver Industrial Demand Rebounded in 2017; Mine Supply Recorded Second Consecutive Loss
NEW YORK, April 12, 2018 (GLOBE NEWSWIRE) -- Industrial demand for silver, fueled by record photovoltaic growth, rose in 2017 for the first time since 2013. A stronger global economy led to healthy demand from the semi-conductor market, resulting in greater silver offtake in electrical and electronics applications as well as brazing alloys and solders. The jewelry and silverware sectors also experienced noteworthy gains in 2017. On the supply side, global mine supply fell for the second consecutive year, following an uninterrupted streak of 13 annual increases prior to 2016. Silver scrap supply, which has been in retreat since 2012, again registered a loss. These factors led to a tightening of the supply/demand balance, contributing to a physical deficit of 26 million ounces (Moz) in 2017, the fifth consecutive annual deficit.These findings, along with other key segments of the silver market, are discussed in World Silver Survey 2018, released today by the Silver Institute and produced on its behalf by the GFMS Team at Thomson Reuters (GFMS).
*Silver Industrial Demand*
Global silver industrial fabrication demand returned to growth in 2017, increasing 4 percent to 599.0 Moz. This was the first rise in silver industrial fabrication since 2013. This growth was bolstered by another year of impressive photovoltaic demand, rising 19 percent in 2017, the result of a 24 percent increase in global solar panel installations. Brazing alloy and solder silver fabrication recorded a 4 percent annual rise to 57.5 Moz, boosted mainly by solid growth from China and Japan.
The surge in electronics, most notably in semi-conductor fabrication demand, led to the electrical and electronics segments delivering the first annual increase in offtake in this category since 2010, with 242.9 Moz consumed last year. Silver demand for the production of ethylene oxide retreated by a third from 2016 volumes to 6.9 Moz, mostly due to a decline in new installations. GFMS estimates that silver’s use in photography, which fell by 3 percent last year to 44.0 Moz, appears to have stabilized, with renewed interest in various photographic applications utilizing silver, only falling marginally over the last few years.
*Silver Jewelry and Silverware Demand*
Silver jewelry demand moved 2 percent higher in 2017 to 209.1 Moz. India was chiefly responsible for the gain, rising 7 percent over 2016 volumes. Demand also picked up strongly in North America, with the United States posting a 12 percent rise to an all-time high. Global demand for silverware jumped by 12 percent last year to 58.4 Moz, led by a strong recovery in demand from India, which experienced a 19 percent increase. North America also posted solid gains, rising 5 percent to 1.6 Moz.
*Silver Supply*
Global silver mine production fell by 4.1 percent in 2017, experiencing its second consecutive annual decline to record 852.1 Moz. The decline was mainly credited to a series of supply disruptions across the Americas. Another leading factor in the drop was due to the primary silver and gold sectors, where production fell by a combined 29.4 Moz. Of the key producing countries, Peru and China registered subtle dips, followed by more acute losses in Australia and Argentina. Offsetting those losses was higher output from Mexico, which was once again the world’s top silver producing country, trailed by Peru, China, Russia and Chile.
Supply from primary silver mines decreased by 9 percent in 2017 to contribute 28 percent of total mine supply. The lead/zinc sector contributed 36 percent of by-product output, followed by copper at 23 percent and gold at 12 percent.
Silver scrap supply fell to 138.1 Moz, marking its sixth successive yearly decline. Lower scrap flows from Asia, mainly China, driven by a lack of incentives from both suppliers and consumers to recycle their valuables, is chiefly responsible for the fall. Supply from the western world was marginally higher, driven by increased volumes from the United States and Europe.
Above-ground stocks rose 3 percent last year. Of the four exchanges that report silver stocks, three saw total silver inventory growth of 2 percent in 2017; COMEX in the United States, the SHFE and the SGE in China. In contrast, silver inventories held at TOCOM declined dramatically by 98 percent, driven by strong industrial demand in Japan.
GFMS reports that government sales of silver were once again absent from the silver market in 2017. Lastly, in the supply category, the delta-adjusted hedge book inched higher by 1.4 Moz, ending last year at 21.5 Moz.
*Silver Price and Investment*
The annual average silver price fell by a slight 0.5 percent to $17.05/oz last year, with prices trading in a $15.22/oz - $18.56/oz range. That said, last year’s average silver price represents an 8.7 percent increase over the average posted just two years ago of $15.68/oz.
Identifiable investment, which consists of net-physical bar investment, coins and medals purchased, and net-changes to exchange traded product (ETP) holdings, reached 153.5 Moz in 2017 a 40 percent decline from the previous year. This was primarily the result of a 35 percent decline in coin and medal fabrication, led by lower demand in the United States, Canada and China. Physical bar demand slipped by 16 percent last year.
In contrast, total global ETP holdings increased by 2.4 Moz to finish 2017 at 669.8 Moz. In value terms, total ETP holdings increased 4 percent to $11.3 billion, as the silver price advanced throughout the year.
*About the World Silver Survey, the Silver Institute and Survey Ordering Information*
The Silver Institute has published this annual report on the global silver market since 1990, to bring dependable supply and demand statistics to market participants and the public.The 28^th edition of the Silver Institute’s World Silver Survey was independently researched and compiled by the GFMS team at Thomson Reuters. World Silver Survey 2018 was sponsored by 20 companies and organizations from North and South America, Europe and Asia.
Copies of World Silver Survey 2018 are available to the media upon request, and a PDF version can be downloaded from the Institute’s website at www.silverinstitute.org. In North America, hard copies may be purchased by the public from the Institute’s website; for copies outside North America, please contact the GFMS team at Thomson Reuters via GFMS@thomsonreuters.com.
*Contact*: Michael DiRienzo, The Silver Institute Johann Wiebe, GFMS Team at Thomson Reuters
+1 202-495-4030 (O) +1 312-408-8761 (O)
mdirienzo@silverinstitute.org johann.wiebe@thomsonreuters.com Reported by GlobeNewswire 55 minutes ago.
*Silver Industrial Demand*
Global silver industrial fabrication demand returned to growth in 2017, increasing 4 percent to 599.0 Moz. This was the first rise in silver industrial fabrication since 2013. This growth was bolstered by another year of impressive photovoltaic demand, rising 19 percent in 2017, the result of a 24 percent increase in global solar panel installations. Brazing alloy and solder silver fabrication recorded a 4 percent annual rise to 57.5 Moz, boosted mainly by solid growth from China and Japan.
The surge in electronics, most notably in semi-conductor fabrication demand, led to the electrical and electronics segments delivering the first annual increase in offtake in this category since 2010, with 242.9 Moz consumed last year. Silver demand for the production of ethylene oxide retreated by a third from 2016 volumes to 6.9 Moz, mostly due to a decline in new installations. GFMS estimates that silver’s use in photography, which fell by 3 percent last year to 44.0 Moz, appears to have stabilized, with renewed interest in various photographic applications utilizing silver, only falling marginally over the last few years.
*Silver Jewelry and Silverware Demand*
Silver jewelry demand moved 2 percent higher in 2017 to 209.1 Moz. India was chiefly responsible for the gain, rising 7 percent over 2016 volumes. Demand also picked up strongly in North America, with the United States posting a 12 percent rise to an all-time high. Global demand for silverware jumped by 12 percent last year to 58.4 Moz, led by a strong recovery in demand from India, which experienced a 19 percent increase. North America also posted solid gains, rising 5 percent to 1.6 Moz.
*Silver Supply*
Global silver mine production fell by 4.1 percent in 2017, experiencing its second consecutive annual decline to record 852.1 Moz. The decline was mainly credited to a series of supply disruptions across the Americas. Another leading factor in the drop was due to the primary silver and gold sectors, where production fell by a combined 29.4 Moz. Of the key producing countries, Peru and China registered subtle dips, followed by more acute losses in Australia and Argentina. Offsetting those losses was higher output from Mexico, which was once again the world’s top silver producing country, trailed by Peru, China, Russia and Chile.
Supply from primary silver mines decreased by 9 percent in 2017 to contribute 28 percent of total mine supply. The lead/zinc sector contributed 36 percent of by-product output, followed by copper at 23 percent and gold at 12 percent.
Silver scrap supply fell to 138.1 Moz, marking its sixth successive yearly decline. Lower scrap flows from Asia, mainly China, driven by a lack of incentives from both suppliers and consumers to recycle their valuables, is chiefly responsible for the fall. Supply from the western world was marginally higher, driven by increased volumes from the United States and Europe.
Above-ground stocks rose 3 percent last year. Of the four exchanges that report silver stocks, three saw total silver inventory growth of 2 percent in 2017; COMEX in the United States, the SHFE and the SGE in China. In contrast, silver inventories held at TOCOM declined dramatically by 98 percent, driven by strong industrial demand in Japan.
GFMS reports that government sales of silver were once again absent from the silver market in 2017. Lastly, in the supply category, the delta-adjusted hedge book inched higher by 1.4 Moz, ending last year at 21.5 Moz.
*Silver Price and Investment*
The annual average silver price fell by a slight 0.5 percent to $17.05/oz last year, with prices trading in a $15.22/oz - $18.56/oz range. That said, last year’s average silver price represents an 8.7 percent increase over the average posted just two years ago of $15.68/oz.
Identifiable investment, which consists of net-physical bar investment, coins and medals purchased, and net-changes to exchange traded product (ETP) holdings, reached 153.5 Moz in 2017 a 40 percent decline from the previous year. This was primarily the result of a 35 percent decline in coin and medal fabrication, led by lower demand in the United States, Canada and China. Physical bar demand slipped by 16 percent last year.
In contrast, total global ETP holdings increased by 2.4 Moz to finish 2017 at 669.8 Moz. In value terms, total ETP holdings increased 4 percent to $11.3 billion, as the silver price advanced throughout the year.
*About the World Silver Survey, the Silver Institute and Survey Ordering Information*
The Silver Institute has published this annual report on the global silver market since 1990, to bring dependable supply and demand statistics to market participants and the public.The 28^th edition of the Silver Institute’s World Silver Survey was independently researched and compiled by the GFMS team at Thomson Reuters. World Silver Survey 2018 was sponsored by 20 companies and organizations from North and South America, Europe and Asia.
Copies of World Silver Survey 2018 are available to the media upon request, and a PDF version can be downloaded from the Institute’s website at www.silverinstitute.org. In North America, hard copies may be purchased by the public from the Institute’s website; for copies outside North America, please contact the GFMS team at Thomson Reuters via GFMS@thomsonreuters.com.
*Contact*: Michael DiRienzo, The Silver Institute Johann Wiebe, GFMS Team at Thomson Reuters
+1 202-495-4030 (O) +1 312-408-8761 (O)
mdirienzo@silverinstitute.org johann.wiebe@thomsonreuters.com Reported by GlobeNewswire 55 minutes ago.
↧
COMMONWEALTH GAMES: Horsham’s Jade Lally finishes seventh in discus final
Horsham’s Jade Lally finished a disappointing seventh place in the women’s discus final at the Commonwealth Games in Australia.
Reported by Crawley Observer 45 minutes ago.
↧
↧
Hockey: Heartbreak for the Indian women's hockey team! Rani Rampal and Co lose 0-1 against Australia in the semi-final. The Indians fought hard but couldn't get the job done. They will now face England in the bronze medal playoff.
Hockey: Heartbreak for the Indian women's hockey team! Rani Rampal and Co lose 0-1 against Australia in the semi-final. The Indians fought hard but couldn't get the job done. They will now face England in the bronze medal playoff.
Select Live Blog:
CWG 2018, Day 8 Live Updates: Sushil Kumar, Rahul Aware win gold as India add six more medals to tally
Live Blog Date:
Thursday, 12 April 2018 - 6:12pm
Short URL:
dnai.in/2
Date published:
Thursday, 12 April 2018 - 6:12pm
Date updated:
Thursday, 12 April 2018 - 6:12pm Reported by DNA 17 minutes ago.
Select Live Blog:
CWG 2018, Day 8 Live Updates: Sushil Kumar, Rahul Aware win gold as India add six more medals to tally
Live Blog Date:
Thursday, 12 April 2018 - 6:12pm
Short URL:
dnai.in/2
Date published:
Thursday, 12 April 2018 - 6:12pm
Date updated:
Thursday, 12 April 2018 - 6:12pm Reported by DNA 17 minutes ago.
↧
TruRating Debuts Plug-In with Magento, Launches Full Online Offering
The original in-store customer feedback solution now first of its kind available in the ecommerce realm
ATLANTA (PRWEB) April 12, 2018
TruRating, a technology company specializing in point-of-payment customer feedback solutions, announced today an official extension with Magento Commerce, the worldwide leader in cloud digital commerce innovation. TruRating is now available for Magento merchants looking to select innovative solutions that enhance business operations.
In addition, the TruRating solution, which began as an in-store service when the company was founded in 2014, is now available to all online retailers, as well as Magento, through a simple initiation process. This means that for the first time, businesses with both online and brick-and-mortar stores can gather customer feedback across those channels, combining ratings with transaction data to gain omnichannel insights that haven’t been possible before.
TruRating’s online business solution, which provides easy-to-understand insights via a dashboard and mobile app, generates a 59 percent quantitative customer response rate and 20 percent qualitative customer response rate, greatly outpacing typical industry standards. All feedback is gathered quickly and efficiently on the payment confirmation page, ensuring that the online shopping experience remains seamless and uninterrupted. Through Magento, digital retailers can go live with TruRating in less than 15 minutes, and for those handling fewer than 10,000 transactions per year, TruRating is free.
“Providing an extension through Magento seems the obvious way to officially launch our online product offering and bring more retailers the customer insights they’re craving,” said TruRating CEO Georgina Nelson. “Nearly 35 percent of businesses around the world use Magento to host their online store.”
The company was launched by Nelson, a former lawyer who wanted to help businesses get better insights by giving a voice to the “silent majority” of consumers who never give reviews. Online shoppers are asked one question on the payment confirmation page that can be answered simply using a number from 0-9, and written responses are also encouraged. The validated customer feedback data is fed back to merchants in near real-time, and the performance dashboard allows them to easily switch between online and brick-and-mortar stores.
“TruRating online is a natural evolution of our wildly successful in-store solution,” said Mary Hubbard, head of consumer product at TruRating. “Having worked with major retail brands in the past, I know firsthand that TruRating addresses well-known blind spots with their customer interactions, particularly as we’re witnessing the rapid change from a traditional customer journey to consumer demand for flexible, personalized, omnichannel shopping experiences.”
Furthermore, TruRating will be attending ETA Transact 2018, April 17-19 in Las Vegas, and Magento’s Imagine 2018 conference, April 23-25 in Las Vegas. If you’re interested in arranging time to speak with an executive at either show, email pr@trurating.com.
TruRating is planning additional ecommerce announcements in Q2. To learn more about how TruRating can help your business, visit trurating.com/business.
About TruRating:
TruRating is a multichannel customer feedback solution for retailers, hospitality and service businesses that utilizes real-time, validated customer feedback at the point of payment (in-store) or payment confirmation page (online). Asked just one question per transaction, a large majority of customers are happy to respond by rating from 0-9 on the keypad or computer. With industry-leading customer response rates, TruRating’s innovative technology platform gives business owners the real-time data they need to make better decisions. Founded in the UK by CEO Georgina Nelson in 2014, TruRating has since expanded operations to Australia, Canada and the United States, and is live in two additional countries, Ireland and New Zealand. Learn more about the ratings revolution at trurating.com. Reported by PRWeb 37 minutes ago.
ATLANTA (PRWEB) April 12, 2018
TruRating, a technology company specializing in point-of-payment customer feedback solutions, announced today an official extension with Magento Commerce, the worldwide leader in cloud digital commerce innovation. TruRating is now available for Magento merchants looking to select innovative solutions that enhance business operations.
In addition, the TruRating solution, which began as an in-store service when the company was founded in 2014, is now available to all online retailers, as well as Magento, through a simple initiation process. This means that for the first time, businesses with both online and brick-and-mortar stores can gather customer feedback across those channels, combining ratings with transaction data to gain omnichannel insights that haven’t been possible before.
TruRating’s online business solution, which provides easy-to-understand insights via a dashboard and mobile app, generates a 59 percent quantitative customer response rate and 20 percent qualitative customer response rate, greatly outpacing typical industry standards. All feedback is gathered quickly and efficiently on the payment confirmation page, ensuring that the online shopping experience remains seamless and uninterrupted. Through Magento, digital retailers can go live with TruRating in less than 15 minutes, and for those handling fewer than 10,000 transactions per year, TruRating is free.
“Providing an extension through Magento seems the obvious way to officially launch our online product offering and bring more retailers the customer insights they’re craving,” said TruRating CEO Georgina Nelson. “Nearly 35 percent of businesses around the world use Magento to host their online store.”
The company was launched by Nelson, a former lawyer who wanted to help businesses get better insights by giving a voice to the “silent majority” of consumers who never give reviews. Online shoppers are asked one question on the payment confirmation page that can be answered simply using a number from 0-9, and written responses are also encouraged. The validated customer feedback data is fed back to merchants in near real-time, and the performance dashboard allows them to easily switch between online and brick-and-mortar stores.
“TruRating online is a natural evolution of our wildly successful in-store solution,” said Mary Hubbard, head of consumer product at TruRating. “Having worked with major retail brands in the past, I know firsthand that TruRating addresses well-known blind spots with their customer interactions, particularly as we’re witnessing the rapid change from a traditional customer journey to consumer demand for flexible, personalized, omnichannel shopping experiences.”
Furthermore, TruRating will be attending ETA Transact 2018, April 17-19 in Las Vegas, and Magento’s Imagine 2018 conference, April 23-25 in Las Vegas. If you’re interested in arranging time to speak with an executive at either show, email pr@trurating.com.
TruRating is planning additional ecommerce announcements in Q2. To learn more about how TruRating can help your business, visit trurating.com/business.
About TruRating:
TruRating is a multichannel customer feedback solution for retailers, hospitality and service businesses that utilizes real-time, validated customer feedback at the point of payment (in-store) or payment confirmation page (online). Asked just one question per transaction, a large majority of customers are happy to respond by rating from 0-9 on the keypad or computer. With industry-leading customer response rates, TruRating’s innovative technology platform gives business owners the real-time data they need to make better decisions. Founded in the UK by CEO Georgina Nelson in 2014, TruRating has since expanded operations to Australia, Canada and the United States, and is live in two additional countries, Ireland and New Zealand. Learn more about the ratings revolution at trurating.com. Reported by PRWeb 37 minutes ago.
↧
Australia's Digitalx Launches Crypto Investment Fund
Australian blockchain and digital advisory company DigitalX has launched a new investment fund called DigitalX Investments, which will focus its investments primarily on major cryptocurrencies such as bitcoin and ether. The cryptocurrency investment fund will also allow diversification into regulated Initial Coin Offerings (ICOs), crypto derivatives, fiat money, and managed investment schemes.
Reported by RTTNews 22 minutes ago.
↧
More Pages to Explore .....
